Markets
IMRX

Immuneering Corp Appoints Andrew Gengos As CFO

June 15, 2026 — 07:55 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16.

Most recently, Gengos served as the Chief Financial Officer at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion.

Prior to Terns Pharmaceuticals, he was the CFO and Chief Business Officer of Athira Pharma, Inc. now LeonaBio, Inc.

In pre-market activity, IMRX shares were trading at $4.24, up 1.41% on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

IMRX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.